Rigin

What is Rigin?

Rigin (Gly-Gln-Pro-Arg) is a tetrapeptide corresponding to residues 341–344 of the human immunoglobulin G (IgG) heavy chain. It was proposed in 1981 as a likely trypsin fragment of IgG that resembled tuftsin (IgG heavy-chain residues 289–292), then synthesized and shown to stimulate phagocytosis as strongly as tuftsin. In its lipidated form — Palmitoyl Tetrapeptide-7 (formerly Palmitoyl Tetrapeptide-3) — it is widely used in cosmeceutical skincare as an anti-inflammatory peptide. Its marketed role in skincare is suppression of IL-6, a pro-inflammatory cytokine that accelerates skin aging by driving chronic low-grade inflammation, though a 2026 cell study also found it raised type III collagen in UV-exposed fibroblasts. It is commonly combined with Palmitoyl Tripeptide-1 in the commercial complex Matrixyl 3000 for synergistic anti-aging effects.

What Rigin Is Investigated For

Rigin is investigated primarily as a cosmeceutical anti-inflammatory peptide — specifically via its palmitoylated form (Palmitoyl Tetrapeptide-7) — with ancillary interest in its original immunological role as a phagocytosis-stimulating IgG fragment. The IL-6 suppression figures usually quoted (40–86% in keratinocytes) are manufacturer data from Sederma that have never appeared in a peer-reviewed paper; the Cosmetic Ingredient Review notes the test protocols and results were not provided. The peer-reviewed human evidence is thin: a 2015 Sederma study found a Pal-GHK + Pal-GQPR blend improved dermal matrix structure versus placebo on skin imaging (PMID 25817264), a 2024 12-week trial of a multi-ingredient eye cream containing palmitoyl tetrapeptide-7 reported better hydration, elasticity, and collagen density but had no placebo arm (PMID 38932444), and a 2026 skin-imaging study showed Pal-GQPR travels through every layer of the stratum corneum between cells (PMID 42790608). The honest caveats are substantial: Rigin is almost never studied as a standalone active — most clinical data comes from multi-ingredient formulations that make attribution difficult, most efficacy work is manufacturer-associated rather than independently replicated, and the chain from in vitro IL-6 suppression to meaningful in vivo anti-aging endpoints in humans is plausible but not rigorously demonstrated. Injectable human use is not established and the immunomodulatory mechanism makes it particularly inadvisable outside a controlled research setting.

History & Discovery

Rigin (Gly-Gln-Pro-Arg) was first described in 1981 by researchers studying tuftsin, the well-characterized phagocytosis-stimulating tetrapeptide from IgG heavy-chain residues 289–292. Using structure-function and conformational analysis, they predicted that trypsin digestion of the IgG heavy chain would also release a tuftsin-like tetrapeptide from residues 341–344, synthesized it, and found its phagocytosis-stimulating activity equal to tuftsin's. Later work characterized its type VII β-turn conformation. The name 'Rigin' reflected its origin in the IgG molecule, and the discovery confirmed a hypothesis that the IgG molecule contains multiple immunomodulatory peptide motifs releasable by proteolytic processing. The peptide remained primarily an immunology research curiosity for two decades — with notable preclinical work on hydrophobic Rigin analogs showing protective effects against Plasmodium berghei malaria in mice via lymphocyte activation pathways — until Sederma (a Croda subsidiary in France) developed the palmitoylated form (Pal-GQPR, INCI palmitoyl tetrapeptide-7, formerly palmitoyl tetrapeptide-3) for cosmeceutical use. The cosmetic positioning was anti-inflammatory rather than collagen-stimulating: Sederma's in vitro work in keratinocytes demonstrated that Pal-GQPR suppresses IL-6 secretion, reducing the chronic low-grade inflammation ('inflammaging') that drives extracellular matrix degradation and skin aging. Pal-GQPR became most widely known as one of the two active components in Sederma's Matrixyl 3000 complex (the other being palmitoyl tripeptide-1, Pal-GHK), where the anti-inflammatory and matrikine mechanisms were positioned as complementary.

How It Works

Rigin calms skin inflammation. It suppresses IL-6, a key inflammatory molecule that accelerates skin aging when chronically elevated. UV exposure spikes IL-6, which breaks down collagen and weakens skin structure. Rigin dials down this inflammatory signal, protecting the skin's structural proteins from inflammatory damage. Separately, it also stimulates immune cells (phagocytes) to clear debris and pathogens.

Rigin (Gly-Gln-Pro-Arg) corresponds to residues 341–344 of the human IgG heavy chain, in the Fc region. It adopts a type VII beta-turn conformation structurally analogous to tuftsin. In its palmitoylated form (Pal-GQPR), it is reported by its manufacturer, Sederma, to suppress IL-6 secretion from keratinocytes — 40–60% at 10–100 μM and up to 86% in UV-irradiated cells — but these results have not been published in a peer-reviewed paper, and the Cosmetic Ingredient Review notes that the protocols and data were not provided. IL-6 drives inflammaging in skin by promoting MMP expression, ECM degradation, and impaired collagen synthesis, so reducing it would indirectly protect ECM integrity. Marketing materials also claim MMP inhibition and increased laminin IV/V and collagen VII, for which we found no indexed source. Independent peer-reviewed data are limited but growing: a 2026 fibroblast study found palmitoyl tetrapeptide-7 increased type III collagen after UV exposure, more so in combination with other peptides (PMID 42683869), and a 2026 skin study showed Pal-GQPR penetrates the full stratum corneum by an intercellular route (PMID 42790608). The unmodified peptide stimulates phagocytosis at levels comparable to tuftsin, activating macrophage-mediated clearance. Hydrophobic analogs (palmitoyl, cholestanyl) showed immunomodulatory protection against Plasmodium berghei in mice, operating through lymphocyte activation rather than macrophage pathways.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Rigin:

• 01Independent, non-industry-funded human trials on Rigin specifically — most cosmetic efficacy data comes from Sederma-associated Matrixyl 3000 studies, and isolated Pal-GQPR clinical trials are essentially absent.
• 02Attribution within multi-component formulations — because Rigin is almost always used in combination with Pal-GHK (Matrixyl 3000) or other peptides, the unique contribution of Pal-GQPR to clinical endpoints is poorly characterized.
• 03Real-world skin-penetration quantification of Pal-GQPR across commercial formulations — a 2026 study confirmed it penetrates the full stratum corneum (PMID 42790608), but how much reaches viable keratinocytes and dermal cells from typical topical products is still not quantified.
• 04Publication of the IL-6 data — the keratinocyte IL-6 suppression figures behind Rigin's positioning are manufacturer data that have never been published in a peer-reviewed paper.
• 05Translation of in vitro IL-6 suppression to in vivo clinical anti-aging endpoints — the mechanistic chain from cytokine modulation in keratinocyte culture to measurable skin-aging outcomes in humans is plausible but not rigorously demonstrated.
• 06Long-term human data — most studies run 8–12 weeks; whether chronic continuous use over years sustains benefit, attenuates, or has any unrecognized signals from sustained immunomodulation has not been studied.
• 07Whether Matrixyl 3000 (Pal-GHK + Pal-GQPR) meaningfully outperforms Pal-GHK alone in robust clinical endpoints — the combination is the dominant commercial form, but head-to-head clinical evidence demonstrating Pal-GQPR adds meaningful benefit beyond Pal-GHK alone is limited.

Forms & Administration

Rigin is primarily used topically as Palmitoyl Tetrapeptide-7 in cosmeceutical formulations (serums, creams, eye treatments). Finished products rarely disclose how much Pal-GQPR they contain; studies summarized by the Cosmetic Ingredient Review used creams at around 15 ppm. It is usually supplied pre-blended with Palmitoyl Tripeptide-1 as Matrixyl 3000. The unmodified peptide is available as a research compound. Topical cosmeceutical use does not require a prescription.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Rigin is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language.

Timeline of Effects

Common Questions

Who Rigin Is NOT For

Drug & Supplement Interactions

Documented pharmacological drug interactions for topical Rigin are minimal. Systemic absorption from typical topical use is low and the palmitoylated tetrapeptide is not expected to reach clinically relevant plasma levels or interact with oral or injected medications. The relevant interaction space is topical layering with other actives. Rigin is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Pal-GHK (palmitoyl tripeptide-1) is standard via the Matrixyl 3000 complex and is the dominant commercial form of Rigin. Layering with neuromuscular peptides (Argireline, SNAP-8, Syn-Ake) combines independent mechanisms cleanly. Pairing with retinoids is generally compatible and complementary (retinoids drive cell turnover; Rigin modulates inflammatory cytokine signaling). High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Rigin can reduce peptide activity at the surface and increase irritation, so spacing is sensible. No documented concern exists with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. Patients on systemic immunosuppressants or biologics for autoimmune disease have no documented interaction with topical Pal-GQPR, but the theoretical immunomodulatory mechanism warrants disclosure to a treating clinician if topical use is on extensive surface area or compromised skin.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions